

Palladium-Catalyzed Oxalyl Amide Assisted Direct *ortho*-Alkynylation of Arylalkylamines Derivatives at δ and ϵ Positions

Mingyu Guan,^a Changpeng Chen,^a Jingyu Zhang,^b Runsheng Zeng^{*a} and Yingsheng Zhao^{*a}

^aCollege of Chemistry, Chemical Engineering and Materials Science, Soochow University,
Suzhou 215123, P. R. China

^bCollege of Physics, Optoelectronics and Energy & Collaborative Innovation Center of Suzhou
Nano Science and Technology, Soochow University, Suzhou 215006, P. R. China

Supporting information


Table of Contents

1. Reagents	S2
2. Instruments.....	S2
3. Preparation of Oxalamide Substrates	S2
4. Optimization of Reaction Conditions	S13
5. <i>ortho</i> -Alkynylation of β -Arylethamine Derivatives	S13
6. <i>ortho</i> -Alkynylation of γ -Arylpropamine Derivatives	S23
7. Gram Scale Reaction	S26
8. Removal of the TIPS.....	S27
9. Removal of the Directing Group	S27
10. Synthesis of 3,4-Dihydroisoquinoline 8a	S28
11. Optimization of Protecting Group	S29
12. Alkynylation of different substituted bromoalkyne	S29
13. Alkynylation of δ -Arylbutamine Derivatives	S30
14. References.....	S30
15. NMR spectra	S31

1. Reagents: Unless otherwise noted, all reagents were purchased from commercial suppliers and used without further purification. Column chromatography purifications were performed using 300–400 mesh silica gel.

2. Instruments: NMR spectra were recorded on Varian Inova–400 MHz, Inova–300 MHz, Bruker DRX–400 or Bruker DRX–500 instruments and calibrated using residual solvent peaks as internal reference. Multiplicities are recorded as: s = singlet, d = doublet, t = triplet, dd = doublet of doublets, br = broad singlet, m = multiplet. HRMS analyses were carried out using a Bruker micrOTOF–Q instrument or a TOF–MS instrument.

3. Preparation of Oxalamide Substrates




3.1 Preparation of N, N-Diisopropylloxamoyl Chloride S1^[1]

A solution of Diisopropylamine (7.01 mL, 50 mmol, 1.0 equiv) in CH₂Cl₂ (50 mL) was added dropwise to a solution of oxalyl chloride (6.44 mL, 75 mmol, 1.5 equiv) in CH₂Cl₂ (100 mL) at 0 °C, after stirring for 5 min, triethylamine (7.30 mL, 52.5 mmol, 1.05 equiv) was added dropwise. The solution was warmed to room temperature and stirred for 6 hours. The excess of oxalyl chloride and the solvent were removed under reduced pressure and CH₂Cl₂ (30 mL) was added and evaporated. This operation was performed twice to give **1f** as a pale yellow solid. The crude product was used in the next step without any purification.

3.2 General procedures for the preparation of oxalamide substrates **1a–1r** (except **1i**, **1k**, **1l**, **1q**), **4a–4h**, **4j**^[2]

A solution of amine (20 mmol, 1.0 equiv) in CH₂Cl₂ (40 mL) was added dropwise to a solution of N,N-Diisopropylloxamoyl chloride **S1** (25 mmol, 1.25 equiv) in CH₂Cl₂ (50 mL) at 0 °C, after stirring for 5 min, triethylamine (2.92 mL, 21 mmol, 1.05 equiv) was added dropwise and then the mixture was stirred for 6 hours at room temperature before quenched by water (50 mL). The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (20 mL × 2). The combined organic phase was washed with brine (30 mL), and then dried over anhydrous Na₂SO₄. Evaporation and column chromatography on silica gel afforded corresponding amide substrates as white solid or colourless liquid with >90% yield.


3.3 Preparation of **1i**^[3]



The first step using 4-(2-aminoethyl)phenol (2.74 g, 20 mmol, 1.0 equiv) as starting material followed the general oxalamide coupling procedure, affording a white solid. The solid was dissolved in DCM


(30 mL) and treated with AcCl (1.56 mL, 22 mmol, 1.1 equiv) and Et₃N (5.56 mL, 40 mmol, 2.0 equiv) at room temperature overnight. Water was added and the mixture was extracted with DCM. The combined organic layer was washed with water and brine, dried over anhydrous Na₂SO₄, and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel to give the product **1i** 4.21 g, 63%.

3.4 Preparation of **1k**^[4]




To a solution of homophenylalanine (3.30g, 20 mmol, 1.0 equiv) in MeOH (30 mL), at 0 °C, was added SOCl₂ (4.35 mL, 60 mmol, 3.0 equiv) dropwise. The resulting mixture was allowed to stir from 0 °C to room temperature overnight. The solvent was removed under reduced pressure to afford a white solid, which was used directly for next step. The second step followed the general oxalamide coupling procedure, to give the product **1k** 5.21 g, 78%.

3.5 Preparation of **1l**



To a solution of homophenylalanine (3.30g, 20 mmol, 1.0 equiv) in MeOH (30 mL), at 0 °C, was added SOCl₂ (4.35 mL, 60 mmol, 3.0 equiv) dropwise. The resulting mixture was allowed to stir from 0 °C to room temperature overnight. The solvent was removed under reduced pressure to afford a white solid, which was used directly for next step. The second step followed the procedure of **1i** to give the product **1l** 5.65 g, 72%.


3.6 Preparation of **1q**^[5]




To a solution of tryptophan (2 g, 10 mmol, 1.0 equiv) in MeOH (20 mL), at 0 °C, was added SOCl₂ (2.1 mL, 30 mmol, 3.0 equiv) dropwise. The resulting mixture was allowed to stir from 0 °C to room temperature overnight. The solvent was removed under reduced pressure to afford a white solid, which was used directly for next step. The second step followed the procedure of **1a**. Then TsCl (15 mmol, 1.5 equiv), NaOH (0.8 g, 20 mmol, 2.0 equiv), TEBAC (3.4 g, 15 mmol, 1.5 equiv) were added, the resulting mixture was allowed to stir at room temperature overnight. Water was added and the mixture was extracted with DCM. The combined organic layer was washed with water and brine, dried over

anhydrous Na_2SO_4 , and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel to give the product **1q** 3.90 g, 74%.


3.7 Preparation of **1q**




SOCl_2 (4.35 mL, 60 mmol, 3.0 equiv) was added dropwise to a solution of amino acid (20 mmol, 1.0 equiv) in MeOH (30 mL) at 0 °C. The resulting mixture was allowed to stir from 0 °C to rt overnight. The solvent was removed under reduced pressure to give white solid, which was used directly for next step. A solution of white solid (20 mmol, 1.0 equiv) in CH_2Cl_2 (40 mL) was added dropwise to a solution of N,N -Diisopropylloxamoyl chloride **S1** (25 mmol, 1.25 equiv) in CH_2Cl_2 (50 mL) at 0 °C, after stirring for 5 min, triethylamine (2.92 mL, 21 mmol, 1.05 equiv) was added dropwise and then the mixture was stirred for 6 hours at room temperature before quenched by water (50 mL). The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (20 mL × 2). The combined organic phase was washed with brine (30 mL), and then dried over anhydrous Na_2SO_4 . Evaporation and column chromatography on silica gel afforded corresponding amide substrates as white solid or colourless oil with >70% yield.




A mixture of **S2** (545 mg, 2 mmol), ArI (3 mmol, 1.5 equiv), $\text{Pd}(\text{OAc})_2$ (22 mg, 5 mol %), Ag_2CO_3 (552 mg, 1.0 equiv), PivOH (61 mg, 0.3 equiv) and 6 mL mesitylene in a 25 mL glass vial was heated at 90 °C with vigorous stirring for 24 hours. The reaction mixture was cooled to room temperature, and diluted with ethyl acetate and filtered through celite. The filtrate was concentrated in vacuo and purified by column chromatography on silica gel (Ethyl acetate/Petroleum ether = 1:20 to 1:2) to give product **4i** 643mg, 85%.




^1H NMR (400 MHz, CDCl_3) δ 7.20 (t, J = 7.6 Hz, 1H), 7.14–7.13 (m, 2H), 6.90–6.84 (m, 2H), 4.62–4.59 (m, 1H), 3.82 (s, 3H), 3.53–3.43 (m, 3H), 2.86 (t, J = 6.7 Hz, 2H), 1.39 (d, J = 6.7 Hz, 6H), 1.18 (d, J = 6.5 Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.41, 157.56, 130.64, 128.00, 127.12, 120.69, 110.36, 55.30, 49.64, 46.45, 39.65, 30.13, 20.92, 20.11. This compound was known.^[5]




¹H NMR (400 MHz, CDCl₃) δ 7.15–7.14 (m, 5H), 4.68–4.62 (m, 1H), 3.53–3.48 (m, 3H), 2.88–2.84 (m, 2H), 2.34 (s, 3H), 1.41 (d, *J* = 6.8 Hz, 6H), 1.21 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.41, 163.28, 136.77, 136.46, 130.55, 129.36, 126.78, 126.24, 49.75, 46.58, 39.47, 32.98, 20.96, 20.15, 19.45. This compound was known. [5]



¹H NMR (400 MHz, CDCl₃) δ 7.20–7.18 (m, 2H), 7.10–7.06 (m, 1H), 7.05–7.00 (m, 1H), 6.93 (br s, 1H), 4.67–4.60 (m, 1H), 3.58–3.53 (m, 2H), 3.51–3.46 (m, 1H), 2.90 (t, *J* = 7.1 Hz, 2H), 1.40 (d, *J* = 6.8 Hz, 6H), 1.22 (t, *J* = 11.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.49, 163.27, 161.40 (d, *J_{C-F}* = 244 Hz), 131.18 (d, *J_{C-F}* = 5.0 Hz), 128.47 (d, *J_{C-F}* = 8.0 Hz), 125.63 (d, *J_{C-F}* = 16.0 Hz), 124.30 (d, *J_{C-F}* = 4.0 Hz), 115.48 (d, *J_{C-F}* = 22.0 Hz), 49.76, 46.55, 39.38, 29.02 (d, *J_{C-F}* = 2.0 Hz), 20.93, 20.15. This compound was known. [5]




¹H NMR (400 MHz, CDCl₃) δ 7.50 (d, *J* = 7.9 Hz, 1H), 7.29 (br s, 1H), 7.26–7.20 (m, 2H), 7.07–7.03 (m, 1H), 4.55–4.52 (m, 1H), 3.57–3.52 (m, 2H), 3.49–3.42 (m, 1H), 2.98 (t, *J* = 7.2 Hz, 2H), 1.37 (d, *J* = 6.8 Hz, 6H), 1.17 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.49, 163.40, 138.04, 132.95, 130.97, 128.32, 127.65, 124.63, 49.73, 46.44, 38.96, 35.65, 20.87, 20.09. This compound was known. [5]




¹H NMR (400 MHz, CDCl₃) δ 7.51–7.46 (m, 2H), 7.43 (t, *J* = 6.7 Hz, 2H), 7.17 (br s, 1H), 4.63–4.57 (m, 1H), 3.60–3.55 (m, 2H), 3.53–3.46 (m, 1H), 2.93 (t, *J* = 7.2 Hz, 2H), 1.40 (d, *J* = 6.8 Hz, 6H), 1.19 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.58, 163.42, 139.68, 132.32, 130.98 (q, *J_{C-F}* =


32 Hz), 129.14, 125.60 (q, $J_{C-F} = 4$ Hz), 124.22 (q, $J_{C-F} = 270$ Hz), 123.55 (q, $J_{C-F} = 4$ Hz), 49.89, 46.58, 40.24, 35.33, 20.86, 20.12. This compound was known.^[5]




¹H NMR (400 MHz, CDCl₃) δ 7.32–7.27 (m, 2H), 7.23–7.20 (m, 3H), 7.11 (br s, 1H), 4.60–4.53 (m, 1H), 3.58–3.53 (m, 2H), 3.52–3.45 (m, 1H), 2.86 (t, $J = 7.2$ Hz, 2H), 1.40 (d, $J = 6.8$ Hz, 6H), 1.19 (d, $J = 6.7$ Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.45, 163.41, 138.68, 128.85, 128.70, 126.62, 49.78, 46.52, 40.53, 35.55, 20.92, 20.16. This compound was known.^[5]




¹H NMR (400 MHz, CDCl₃) δ 8.18–8.16 (m, 2H), 7.40–7.38 (m, 2H), 7.14 (br s, 1H), 4.63–4.57 (m, 1H), 3.61–3.55 (m, 2H), 3.53–3.46 (m, 1H), 2.97 (t, $J = 7.1$ Hz, 2H), 1.39 (d, $J = 6.8$ Hz, 6H), 1.19 (d, $J = 6.7$ Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.52, 163.16, 146.94, 146.53, 129.80, 123.92, 49.87, 46.64, 39.96, 35.47, 20.91, 20.13. This compound was known.^[5]




¹H NMR (400 MHz, CDCl₃) δ 7.12 (d, $J = 8.6$ Hz, 4H), 6.95 (br s, 1H), 4.65–4.58 (m, 1H), 3.55–3.45 (m, 3H), 2.81 (t, $J = 7.2$ Hz, 2H), 2.31 (s, 3H), 1.40 (d, $J = 6.8$ Hz, 6H), 1.19 (d, $J = 6.7$ Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.38, 163.26, 136.18, 135.53, 129.44, 128.74, 49.75, 46.58, 40.68, 35.14, 21.14, 20.96, 20.18. This compound was known.^[5]




¹H NMR (400 MHz, CDCl₃) δ 7.21 (d, $J = 8.4$ Hz, 3H), 6.99 (d, $J = 8.4$ Hz, 2H), 4.52–4.47 (m, 1H), 3.54–3.49 (m, 2H), 3.48–3.43 (m, 1H), 2.82 (t, $J = 7.2$ Hz, 2H), 2.26 (s, 3H), 1.38 (d, $J = 6.8$ Hz, 6H), 1.17 (d, $J = 6.6$ Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 169.58, 163.54, 163.52, 149.34, 136.26, 129.77, 121.69, 49.82, 46.42, 40.38, 34.88, 21.17, 20.85, 20.11. This compound was known.^[5]




¹H NMR (400 MHz, CDCl₃) δ 7.30 (t, *J* = 7.6 Hz, 2H), 7.23–7.19 (m, 3H), 6.94 (br s, 1H), 4.42–4.37 (m, 1H), 3.54–3.39 (m, 3H), 3.03–2.94 (m, 1H), 1.38–1.35 (m, 6H), 1.28 (d, *J* = 7.0 Hz, 3H), 1.16–1.12 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.54, 143.93, 128.72, 127.28, 126.77, 49.83, 46.40, 45.86, 39.78, 20.88, 20.16, 20.14, 19.45. This compound was known. [5]




¹H NMR (400 MHz, CDCl₃) δ 7.30–7.16 (m, 6H), 4.87–4.84 (m, 1H), 4.39–4.34 (m, 1H), 3.72 (s, 3H), 3.49–3.46 (m, 1H), 3.22–3.07 (m, 2H), 1.42–1.40 (m, 6H), 1.18–1.16 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 171.32, 162.95, 135.74, 129.34, 128.69, 127.21, 53.24, 52.52, 49.81, 46.50, 38.03, 20.90, 20.81, 20.10. This compound was known. [5]




¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J* = 8.5 Hz, 3H), 7.11 (br s, 1H), 7.04 – 7.00 (m, 2H), 4.86 – 4.81 (m, 1H), 4.47 – 4.41 (m, 1H), 3.71 (s, 3H), 3.53 – 3.45 (m, 1H), 3.17 (dd, *J* = 14.0, 5.8 Hz, 1H), 3.08 (dd, *J* = 14.0, 6.7 Hz, 1H), 2.27 (s, 4H), 1.41 (dd, *J* = 6.8, 2.7 Hz, 7H), 1.18 (d, *J* = 6.6 Hz, 7H); ¹³C NMR (101 MHz, CDCl₃) δ 171.17, 169.47, 162.94, 162.53, 149.95, 133.37, 130.41, 121.86, 53.25, 52.60, 49.83, 46.63, 37.55, 21.25, 20.94, 20.90, 20.17; HRMS (ESI-TOF) m/z [M–H⁺] Calcd for C₂₀H₂₇N₂O₆: 391.1869; Found: 391.1865.




¹H NMR (400 MHz, CDCl₃) δ 7.03 (br s, 1H), 6.81–6.78 (m, 1H), 6.74 (dd, *J* = 5.9, 1.8 Hz, 2H), 4.61–4.54 (m, 1H), 3.85 (d, *J* = 9.5 Hz, 6H), 3.54–3.44 (m, 3H), 2.78 (t, *J* = 7.1 Hz, 2H), 1.38 (d, *J* = 6.8 Hz, 6H), 1.18 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.41, 163.29, 149.09, 147.80, 131.16, 120.77, 112.02, 111.45, 56.00, 55.94, 49.76, 46.54, 40.60, 35.16, 20.91, 20.14. This compound was known. [4]




^1H NMR (400 MHz, CDCl_3) δ 7.37 (br s, 1H), 7.28 (s, 1H), 7.22–7.17 (m, 2H), 4.57–4.52 (m, 1H), 3.57–3.52 (m, 2H), 3.51–3.46 (m, 1H), 2.97 (t, $J = 7.1$ Hz, 2H), 1.40 (d, $J = 6.8$ Hz, 6H), 1.20 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.52, 163.26, 134.99, 134.92, 133.12, 131.82, 129.45, 127.29, 49.81, 46.55, 38.71, 32.76, 20.90, 20.12. This compound was known. [5]




^1H NMR (400 MHz, CDCl_3) δ 7.31 (br s, 1H), 7.04 (d, $J = 7.6$ Hz, 1H), 7.00–6.90 (m, 2H), 4.64 (m, 1H), 3.60–3.35 (m, 3H), 2.92–2.71 (m, 2H), 2.29 (d, $J = 4.9$ Hz, 6H), 1.41 (d, $J = 6.8$ Hz, 6H), 1.22 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.55, 163.46, 136.54, 135.46, 133.16, 130.30, 130.05, 127.30, 53.51, 49.73, 46.40, 39.48, 32.85, 20.89, 20.82, 20.05, 18.83. This compound was known. [5]




^1H NMR (400 MHz, CDCl_3) δ 7.29 (br s, 1H), 7.13 (d, $J = 4.9$ Hz, 1H), 6.93 – 6.90 (m, 1H), 6.85 (s, 1H), 4.59 – 4.52 (m, 1H), 3.55 (dd, $J = 13.1, 6.6$ Hz, 2H), 3.51 – 3.44 (m, 1H), 3.06 (t, $J = 6.8$ Hz, 2H), 1.39 (d, $J = 6.8$ Hz, 6H), 1.19 (d, $J = 6.6$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.50, 163.42, 140.98, 127.09, 125.47, 123.95, 49.81, 46.47, 40.69, 29.63, 20.88, 20.13; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for $\text{C}_{14}\text{H}_{22}\text{N}_2\text{O}_2\text{SNa}$: 305.1300; found: 305.1299.




^1H NMR (400 MHz, CDCl_3) δ 7.95 (d, $J = 8.2$ Hz, 1H), 7.76 (d, $J = 8.4$ Hz, 2H), 7.48 (d, $J = 7.7$ Hz, 1H), 7.43 (s, 1H), 7.33–7.27 (m, 2H), 7.25–7.19 (m, 3H), 4.87 (m, $J = 8.0, 6.1$ Hz, 1H), 4.56 (m, $J = 13.3, 6.7$ Hz, 1H), 3.62 (s, 3H), 3.50 (m, $J = 13.6, 6.8$ Hz, 1H), 3.24 (t, $J = 6.4$ Hz, 2H), 2.33 (s, 3H), 1.42 (dd, $J = 6.8, 3.1$ Hz, 6H), 1.19 (t, $J = 6.4$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 171.19, 162.95, 162.27, 145.01, 135.23, 135.16, 130.67, 130.02, 127.01, 125.04, 124.71, 123.39, 119.45, 116.85, 113.83, 52.68, 52.27, 49.84, 46.73, 27.73, 21.71, 20.94, 20.92, 20.17; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for $\text{C}_{27}\text{H}_{33}\text{N}_3\text{O}_6\text{S}$: 550.1988; Found: 550.1997.




¹H NMR (400 MHz, CDCl₃) δ 6.81 (br s, 1H), 5.48 (s, 1H), 4.70 (m, 1H), 3.50 (m, 1H), 3.35 (m, 2H), 2.16 (t, *J* = 6.8 Hz, 2H), 1.97 (m, 4H), 1.65–1.58 (m, 2H), 1.57–1.50 (m, 2H), 1.41 (d, *J* = 6.8 Hz, 6H), 1.22 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.32, 163.27, 134.38, 123.73, 49.77, 46.60, 37.52, 37.36, 28.10, 25.36, 22.94, 22.44, 21.01, 20.22; HRMS (ESI-TOF) m/z [M+Na⁺] Calcd for C₁₅H₂₆N₂NaO₂: 289.1892; Found: 289.1901.




¹H NMR (400 MHz, CDCl₃) δ 7.08 (br s, 1H), 6.73 (d, *J* = 7.9 Hz, 1H), 6.69 (d, *J* = 1.4 Hz, 1H), 6.65 (dd, *J* = 7.9, 1.6 Hz, 1H), 5.91 (s, 2H), 4.62–4.55 (m, 1H), 3.51–3.44(m, 3H), 2.76 (t, *J* = 7.1 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.19 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.41, 163.33, 147.87, 146.30, 132.39, 121.77, 109.18, 108.46, 100.99, 49.79, 46.54, 40.73, 35.24, 20.92, 20.15. This compound was known.^[4]




¹H NMR (400 MHz, CDCl₃) δ 7.01 (br s, 1H), 5.82 – 5.71 (m, 1H), 5.15 – 5.06 (m, 2H), 4.72 – 4.67 (m, 1H), 3.51 – 3.46 (m, 1H), 3.35 (dd, *J* = 12.9, 6.7 Hz, 2H), 2.33 – 2.26 (m, 2H), 1.40 (d, *J* = 6.8 Hz, 6H), 1.21 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.43, 134.99, 117.39, 49.76, 46.53, 38.46, 33.48, 20.92, 20.16; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₁₂H₂₂N₂O₂Na: 249.1579; found: 249.1580.




¹H NMR (400 MHz, CDCl₃) δ 7.22–7.18 (m, 1H), 7.10 (br s, 1H), 6.80 (d, *J* = 7.7 Hz, 1H), 6.77–6.75 (m, 2H), 4.58–4.52 (m, 1H), 3.78 (s, 3H), 3.56–3.51 (m, 2H), 3.49–3.44 (m, 1H), 2.82 (t, *J* = 7.2 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.18 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.46, 159.87, 140.22, 129.68, 121.15, 114.36, 112.18, 55.25, 49.80, 46.50, 40.39, 35.57, 20.90, 20.14. This compound was known.^[5]




¹H NMR (400 MHz, CDCl₃) δ 7.23 (d, *J* = 7.6 Hz, 1H), 7.21–7.17 (m, 3H), 7.10 (d, *J* = 7.0 Hz, 1H), 4.53–4.46 (m, 1H), 3.56–3.50 (m, 2H), 3.49–3.44 (m, 1H), 2.83 (t, *J* = 7.2 Hz, 2H), 1.38 (d, *J* = 6.8 Hz, 6H), 1.18 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.55, 163.45, 140.75, 134.40, 129.94, 128.99, 127.07, 126.83, 49.90, 46.54, 40.21, 35.16, 20.91, 20.15. This compound was known. [5]




¹H NMR (400 MHz, CDCl₃) δ 7.45 (br s, 1H), 7.38 (s, 1H), 7.35–7.34 (m, 1H), 7.16 (d, *J* = 4.6 Hz, 2H), 4.46–4.41 (m, 1H), 3.57–3.52 (m, 2H), 3.50–3.44 (m, 1H), 2.84 (t, *J* = 7.2 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.19 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.65, 163.61, 141.08, 131.85, 130.15, 129.66, 127.49, 122.58, 49.93, 46.40, 40.11, 35.03, 20.85, 20.11. This compound was known. [5]




¹H NMR (400 MHz, CDCl₃) δ 7.48 (br s, 1H), 6.98–6.87 (m, 4H), 4.67–4.61 (m, 1H), 4.13–4.10 (m, 2H), 3.86 (s, 3H), 3.70–3.66 (m, 2H), 3.53–3.46 (m, 1H), 1.42 (d, *J* = 6.6 Hz, 6H), 1.21 (d, *J* = 6.4 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 184.72, 171.32, 162.95, 135.74, 129.34, 128.69, 127.21, 53.24, 52.52, 49.81, 46.50, 38.03, 20.90, 20.81, 20.10. This compound was known. [5]




¹H NMR (400 MHz, CDCl₃) δ 7.32 (br s, 1H), 7.11 – 7.01 (m, 2H), 7.09–7.02 (m, 2H), 4.68–4.64 (m, 1H), 4.14 (t, *J* = 5.2 Hz, 2H), 3.74–3.70 (m, 2H), 3.54–3.47 (m, 1H), 1.41 (d, *J* = 6.8 Hz, 6H), 1.22 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.66, 162.91, 152.92 (d, *J*_{C-F} = 244 Hz), 146.65 (d, *J*_{C-F} = 10 Hz), 124.50 (d, *J*_{C-F} = 4 Hz), 121.98 (d, *J*_{C-F} = 7 Hz), 116.49 (d, *J*_{C-F} = 18 Hz), 115.56, 68.04, 49.85, 46.67, 38.89, 20.95, 20.16. This compound was known. [5]




^1H NMR (400 MHz, CDCl_3) δ 7.35 (dd, $J = 8.2, 1.6$ Hz, 1H), 7.30 (br s, 1H), 7.22–7.18 (m, 1H), 6.93–6.89 (m, 2H), 4.69–4.66 (m, 1H), 4.13 (t, $J = 5.2$ Hz, 2H), 3.77–3.73 (m, 2H), 3.52–3.49 (m, 1H), 1.42 (d, $J = 6.8$ Hz, 6H), 1.22 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.63, 162.87, 154.07, 130.51, 127.92, 123.35, 122.22, 114.04, 67.80, 49.81, 46.69, 38.81, 20.98, 20.17. This compound was known.^[5]




^1H NMR (400 MHz, CDCl_3) δ 7.38 (br s, 1H), 7.14 (t, $J = 6.7$ Hz, 2H), 6.87 (t, $J = 7.4$ Hz, 1H), 6.79 (d, $J = 8.4$ Hz, 1H), 4.78–4.74 (m, 1H), 4.07 (t, $J = 5.2$ Hz, 2H), 3.74–3.70 (m, 2H), 3.53–3.49 (m, 1H), 2.23 (s, 3H), 1.42 (d, $J = 6.8$ Hz, 6H), 1.22 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.39, 162.78, 156.58, 130.90, 126.93, 120.98, 111.08, 66.39, 49.73, 46.71, 39.07, 20.97, 20.15, 16.37. This compound was known.^[5]




^1H NMR (400 MHz, CDCl_3) δ 7.51 (br s, 1H), 7.17 (t, $J = 8.1$ Hz, 1H), 6.92 (d, $J = 7.9$ Hz, 1H), 6.86 (s, 1H), 6.76 (d, $J = 8.1$ Hz, 1H), 4.69–4.62 (m, 1H), 4.03 (t, $J = 5.2$ Hz, 2H), 3.69–3.65 (m, 2H), 3.52–3.45 (m, 1H), 1.39 (d, $J = 6.8$ Hz, 6H), 1.20 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.51, 162.94, 159.17, 134.94, 130.36, 121.37, 115.01, 112.95, 66.47, 49.81, 46.62, 38.72, 20.90, 20.11. This compound was known.^[5]




^1H NMR (400 MHz, CDCl_3) δ 7.43 (br s, 1H), 7.14 (t, $J = 7.8$ Hz, 1H), 6.76 (d, $J = 7.5$ Hz, 1H), 6.71 (s, 1H), 6.68 (d, $J = 8.2$ Hz, 1H), 4.71 – 4.67 (m, 1H), 4.04 (t, $J = 5.2$ Hz, 2H), 3.68 (dd, $J = 10.9, 5.5$ Hz, 2H), 3.53 – 3.46 (m, 1H), 2.31 (s, 3H), 1.41 (d, $J = 6.8$ Hz, 6H), 1.21 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.50, 162.99, 158.46, 139.61, 129.30, 122.03, 115.43, 111.38, 66.10, 49.74, 46.59, 38.90, 21.56, 20.90, 20.12; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for $\text{C}_{17}\text{H}_{25}\text{N}_2\text{O}_3\text{Na}$: 329.1841; found: 329.1838.




^1H NMR (400 MHz, CDCl_3) δ 7.31–7.23 (m, 8H), 7.18 (t, $J = 6.9$ Hz, 2H), 6.96 (br s, 1H), 4.80–4.74 (m, 1H), 3.99 (t, $J = 7.9$ Hz, 1H), 3.54–3.48 (m, 1H), 3.26–3.21 (m, 2H), 2.36–2.30 (m, 2H), 1.42 (d, $J = 6.8$ Hz, 6H), 1.22 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.28, 163.16, 144.06, 128.70, 127.83, 126.51, 49.71, 48.89, 46.61, 38.22, 34.83, 20.97, 20.17. This compound was known. [5]



^1H NMR (400 MHz, CDCl_3) δ 7.32–7.28 (m, 2H), 7.22–7.19 (m, 3H), 7.12 (br s, 1H), 4.79–4.73 (m, 1H), 3.55–3.50 (m, 1H), 3.36–3.31 (m, 2H), 2.71–2.67 (m, 2H), 1.94–1.87 (m, 2H), 1.44 (d, $J = 6.8$ Hz, 6H), 1.25 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.36, 163.26, 141.32, 128.57, 128.49, 126.13, 49.77, 46.67, 39.03, 33.28, 30.92, 20.98, 20.19. This compound was known. [5]



^1H NMR (400 MHz, CDCl_3) δ 7.33 (d, $J = 7.9$ Hz, 1H), 7.08 (d, $J = 8.4$ Hz, 2H), 6.81 (d, $J = 8.5$ Hz, 2H), 4.68–4.62 (m, 1H), 4.59–4.54 (m, 1H), 3.74 (d, $J = 20.0$ Hz, 6H), 3.55–3.48 (m, 1H), 2.63 (t, $J = 7.9$ Hz, 2H), 2.23–2.14 (m, 1H), 2.07–1.98 (m, 1H), 1.43 (d, $J = 6.8$ Hz, 6H), 1.23 (dd, $J = 6.4, 4.1$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 172.02, 163.15, 162.61, 158.15, 132.48, 129.47, 114.01, 55.34, 52.56, 51.98, 49.79, 46.68, 34.01, 30.82, 20.97, 20.94, 20.22, 20.14; HRMS (ESI-TOF) m/z [M+H $^+$] Calcd for $\text{C}_{20}\text{H}_{31}\text{N}_2\text{O}_5$: 379.2233; Found: 379.2230.



^1H NMR (400 MHz, CDCl_3) δ 7.26 (t, $J = 7.4$ Hz, 2H), 7.17 (dd, $J = 10.4, 4.5$ Hz, 3H), 4.68 (br s, 1H), 3.53–3.46 (m, 1H), 3.29 (dd, $J = 13.1, 6.8$ Hz, 2H), 2.63 (t, $J = 7.5$ Hz, 2H), 1.71–1.63 (m, 2H), 1.62–1.54 (m, 2H), 1.41 (d, $J = 6.8$ Hz, 6H), 1.21 (d, $J = 6.7$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.38, 142.11, 128.47, 128.39, 125.87, 49.75, 46.54, 39.18, 35.51, 28.87, 28.73, 20.91, 20.15; HRMS (ESI-TOF) m/z [M+H $^+$] Calcd for $\text{C}_{18}\text{H}_{29}\text{N}_2\text{O}_2$: 305.2229; Found: 305.2231.


4. Optimization of Reaction Conditions^a

Table 1S Optimization of Reaction Conditions


	1a	2		3a
entry	Pd(OAc) ₂ (mol %)	base	additive (equiv)	Yield (%)
1	5	—	AgOAc (2), PivOH (0.3)	67
2	5	LiOAc	—	4
3	5	NaOAc	—	31
4	5	KOAc	—	62
5	5	CsOAc	—	93(85 ^b)
6	5	Na ₂ CO ₃	—	22
7	5	K ₂ CO ₃	—	36
8	5	KHCO ₃	—	56
9	5	Na ₂ CO ₃	PivOH (0.3)	47
10	5	K ₂ CO ₃	PivOH (0.3)	36
11	5	CsOAc	PivOH (0.3)	51
12	—	CsOAc	—	NR

^aReaction conditions: **1a** (0.1 mmol), **2** (0.12 mmol), Pd(OAc)₂ (5 mol %), base (2 equiv), toluene (0.5 mL), 100 °C, air, 24 h. Yield was based on LC using acetophenone as the internal standard. ^bIsolated yield at 0.2 mmol scale.


5. *ortho*-Alkynylation of β -Arylethamine Derivatives




A mixture of **1** (0.2 mmol, 1.0 equiv), **2** (0.24 mmol, 1.2 equiv), Pd(OAc)₂ (1.1 mg, 0.05 equiv), CsOAc (76.8 mg, 2 equiv), toluene (0.5 mL) in a 15 mL glass vial (sealed with PTFE cap) was heated at 80 °C for 24 hours. The reaction mixture was cooled to rt, and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel to give the alkynylation product.




¹H NMR (400 MHz, CDCl₃) δ 7.14 (br s, 1H), 7.11 (d, *J* = 7.8 Hz, 1H), 7.10 – 7.07 (m, 1H), 6.83 (d, *J* = 7.6 Hz, 1H), 4.64 – 4.57 (m, 1H), 3.83 (s, 3H), 3.53 (dd, *J* = 12.2, 6.2 Hz, 2H), 3.48 – 3.42 (m, 1H), 3.15 (t, *J* = 6.6 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.15 (d, *J* = 6.7 Hz, 6H), 1.12 (s, 18H), 1.10 – 1.04 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.26, 163.14, 157.56, 129.75, 127.42, 125.30, 124.75, 110.88, 105.09, 94.78, 55.63, 49.45, 46.43, 39.60, 27.41, 20.92, 20.08, 18.77, 11.39; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₈H₄₆N₂O₃SiNa: 509.3175; found: 509.3177.




¹H NMR (400 MHz, CDCl₃) δ 7.34 (d, *J* = 7.1 Hz, 1H), 7.12 (d, *J* = 7.2 Hz, 1H), 7.06 (t, *J* = 7.6 Hz, 1H), 6.92 (br s, 1H), 4.68 – 4.62 (m, 1H), 3.55 (dd, *J* = 14.4, 6.6 Hz, 2H), 3.52 – 3.45 (m, 1H), 3.14 (t, *J* = 7.4 Hz, 2H), 2.38 (s, 3H), 1.41 (d, *J* = 6.8 Hz, 6H), 1.20 (d, *J* = 6.7 Hz, 6H), 1.13 (s, 18H), 1.12 – 1.06 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.34, 163.02, 138.99, 137.16, 131.04, 130.94, 126.39, 123.81, 106.03, 94.24, 49.59, 46.59, 38.97, 31.20, 20.99, 20.14, 19.93, 18.83, 11.46; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₈H₄₆N₂O₂SiNa: 493.3226; found: 493.3217.



¹H NMR (400 MHz, CDCl₃) δ 7.29 (d, *J* = 7.1 Hz, 1H), 7.17 – 7.12 (m, 1H), 7.01 (t, *J* = 8.6 Hz, 1H), 6.90 (br s, 1H), 4.64 – 4.57 (m, 1H), 3.63 – 3.58 (m, 2H), 3.51 – 3.44 (m, 1H), 3.13 (t, *J* = 6.3 Hz, 2H), 1.40 (d, *J* = 6.8 Hz, 6H), 1.19 (d, *J* = 6.7 Hz, 6H), 1.13 (d, *J* = 2.8 Hz, 18H), 1.10 (dd, *J* = 9.8, 4.9 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.34, 163.08, 161.30 (d, *J*_{C-F} = 244 Hz), 128.86, 128.06 (d, *J*_{C-F} = 17 Hz), 127.86 (d, *J*_{C-F} = 9 Hz), 125.61 (d, *J*_{C-F} = 5 Hz), 115.85 (d, *J*_{C-F} = 23 Hz), 103.87 (d, *J*_{C-F} = 4 Hz), 96.13, 49.60, 46.49, 38.88, 27.23, 20.90, 20.11, 18.75, 11.35; ¹⁹F NMR (376 MHz, CDCl₃) δ -116.66; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₇H₄₃FN₂O₂SiNa: 497.2976; found: 497.2972.




¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, *J* = 8.0 Hz, 1H), 7.43 (dd, *J* = 7.4, 3.4 Hz, 1H), 7.02 (d, *J* = 7.7 Hz, 1H), 6.97 (br s, 1H), 4.70 – 4.64 (m, 1H), 3.62 (dd, *J* = 13.4, 6.9 Hz, 2H), 3.50 – 3.44 (m, 1H), 3.29 (dd, *J* = 9.1, 5.1 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.18 (d, *J* = 6.7 Hz, 6H), 1.16 – 1.11 (m, 18H), 1.08 (dd, *J* = 11.0, 3.5 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.09, 162.86, 140.18, 133.28, 132.42, 127.83, 125.53, 125.18, 104.48, 96.30, 49.50, 46.59, 38.58, 34.36, 20.97, 20.13, 18.78, 11.37; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₇H₄₃BrN₂O₂SiNa: 557.2175; found: 557.2161.




¹H NMR (400 MHz, CDCl₃) δ 7.57 (d, *J* = 8.0 Hz, 1H), 7.46 (s, 1H), 7.42 (d, *J* = 8.0 Hz, 1H), 7.11 (br s, 1H), 4.67 – 4.60 (m, 1H), 3.64 – 3.59 (m, 2H), 3.51 – 3.44 (m, 1H), 3.11 (dd, *J* = 8.9, 5.1 Hz, 2H),


1.38 (d, $J = 6.8$ Hz, 6H), 1.18 (d, $J = 6.7$ Hz, 6H), 1.13 (t, $J = 3.7$ Hz, 18H), 1.09 (dd, $J = 11.0, 3.4$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.37, 162.93, 141.69, 133.44, 130.26 (q, $J_{\text{C}-\text{F}} = 32$ Hz), 127.60, 126.19 (d, $J_{\text{C}-\text{F}} = 3$ Hz), 123.91 (q, $J_{\text{C}-\text{F}} = 271$ Hz), 123.41 (d, $J_{\text{C}-\text{F}} = 3$ Hz), 103.74, 98.22, 49.70, 46.61, 39.28, 34.30, 20.86, 20.06, 18.74, 11.34; ^{19}F NMR (376 MHz, CDCl_3) δ -62.75; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{28}\text{H}_{43}\text{F}_3\text{N}_2\text{O}_2\text{SiNa}$: 547.2944; found: 547.2948.




^1H NMR (400 MHz, CDCl_3) δ 7.48 (d, $J = 7.3$ Hz, 1H), 7.26 (dd, $J = 7.6, 6.0$ Hz, 1H), 7.22 (d, $J = 6.1$ Hz, 1H), 7.20 – 7.16 (m, 1H), 6.82 (br s, 1H), 4.63 – 4.57 (m, 1H), 3.64 – 3.59 (m, 2H), 3.52 – 3.45 (m, 1H), 3.06 (t, $J = 6.9$ Hz, 2H), 1.40 (d, $J = 6.8$ Hz, 6H), 1.20 (d, $J = 6.7$ Hz, 6H), 1.13 (s, 18H), 1.07 (dd, $J = 13.0, 7.9$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.42, 163.21, 140.81, 133.22, 129.54, 128.80, 126.65, 123.32, 105.21, 95.04, 49.76, 46.58, 39.56, 34.40, 20.98, 20.16, 18.83, 11.43; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{27}\text{H}_{44}\text{N}_2\text{O}_2\text{SiNa}$: 479.3070; found: 479.3063.




^1H NMR (400 MHz, CDCl_3) δ 7.43 (d, $J = 7.7$ Hz, 2H), 7.12 (t, $J = 7.7$ Hz, 1H), 6.88 (br s, 1H), 4.61 – 4.53 (m, 1H), 3.65 (dd, $J = 12.8, 7.1$ Hz, 2H), 3.48 – 3.42 (m, 1H), 3.34 (dd, $J = 9.3, 5.0$ Hz, 2H), 1.38 (d, $J = 6.8$ Hz, 6H), 1.16 (s, 6H), 1.12 (d, $J = 2.5$ Hz, 36H), 1.11 – 1.06 (m, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 162.94, 162.86, 142.74, 133.17, 126.45, 124.09, 104.77, 95.48, 49.45, 46.52, 39.30, 32.61, 20.99, 20.17, 18.83, 11.43; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{38}\text{H}_{64}\text{N}_2\text{O}_2\text{SiNa}$: 659.4404; found: 659.4410.




^1H NMR (400 MHz, CDCl_3) δ 8.28 (d, $J = 2.4$ Hz, 1H), 8.08 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.40 (d, $J = 8.5$ Hz, 1H), 7.02 (br s, 1H), 4.63 – 4.56 (m, 1H), 3.65 – 3.60 (m, 2H), 3.52 – 3.45 (m, 1H), 3.15 (dd, $J = 8.7, 4.8$ Hz, 2H), 1.38 (d, $J = 6.8$ Hz, 6H), 1.19 (d, $J = 6.7$ Hz, 6H), 1.16 – 1.12 (m, 18H), 1.12 – 1.06 (m, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.42, 162.82, 148.16, 146.67, 130.53, 127.81, 124.86, 123.23, 102.62, 98.61, 49.71, 46.65, 38.97, 34.53, 20.94, 20.12, 18.77, 11.33; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{27}\text{H}_{43}\text{N}_3\text{O}_4\text{SiNa}$: 524.2921; found: 524.2914.




¹H NMR (400 MHz, CDCl₃) δ 8.22 (s, 2H), 6.95 (br s, 1H), 4.62 – 4.55 (m, 1H), 3.67 (dd, *J* = 13.1, 6.9 Hz, 2H), 3.47 (dd, *J* = 13.6, 6.8 Hz, 1H), 3.43 – 3.38 (m, 2H), 1.38 (d, *J* = 6.8 Hz, 6H), 1.16 (s, 6H), 1.15 – 1.12 (m, 36H), 1.12 – 1.06 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 162.82, 162.36, 149.62, 146.24, 127.10, 125.70, 102.46, 99.04, 49.43, 46.68, 38.65, 33.23, 20.96, 20.13, 18.81, 11.35; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₃₈H₆₃N₃O₄Si₂Na: 704.4255; found: 704.4239.



¹H NMR (400 MHz, CDCl₃) δ 7.29 (s, 1H), 7.11 (d, *J* = 7.8 Hz, 1H), 7.08 – 7.05 (m, 1H), 6.80 (br s, 1H), 4.63 – 4.56 (m, 1H), 3.61 – 3.56 (m, 2H), 3.51 – 3.44 (m, 1H), 3.01 (t, *J* = 6.9 Hz, 2H), 2.28 (s, 3H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.19 (d, *J* = 6.7 Hz, 6H), 1.13 (s, 18H), 1.07 (dd, *J* = 10.2, 5.3 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.38, 163.20, 137.78, 136.25, 133.62, 129.69, 129.44, 123.07, 105.46, 94.48, 49.70, 46.55, 39.66, 33.92, 20.96, 20.85, 20.16, 18.82, 11.44; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₈H₄₆N₂O₂SiNa: 493.3226; found: 493.3226.




¹H NMR (400 MHz, CDCl₃) δ 7.26 (s, 2H), 6.87 (br s, 1H), 4.60 – 4.54 (m, 1H), 3.63 (dd, *J* = 12.7, 7.0 Hz, 2H), 3.49 – 3.42 (m, 1H), 3.30 (dd, *J* = 9.2, 5.0 Hz, 2H), 2.27 (s, 3H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.16 (d, *J* = 6.7 Hz, 6H), 1.13 (d, *J* = 1.9 Hz, 36H), 1.11 – 1.06 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 162.95, 162.89, 139.85, 136.16, 133.84, 123.88, 105.01, 94.92, 49.46, 46.53, 39.42, 32.13, 20.99, 20.64, 20.18, 18.84, 11.44; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₃₉H₆₆N₂O₂Si₂Na: 673.4561; found: 673.4559.




¹H NMR (400 MHz, CDCl₃) δ 7.23 (d, *J* = 8.3 Hz, 1H), 7.20 (d, *J* = 2.5 Hz, 1H), 6.99 (dd, *J* = 8.3, 2.5 Hz, 1H), 6.82 (br s, 1H), 4.63 – 4.57 (m, 1H), 3.61 – 3.56 (m, 2H), 3.51 – 3.44 (m, 1H), 3.03 (dd, *J* =


8.7, 5.0 Hz, 2H), 2.27 (s, 3H), 1.39 (d, J = 6.8 Hz, 6H), 1.20 (d, J = 6.7 Hz, 6H), 1.15 – 1.11 (m, 18H), 1.11 – 1.04 (m, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 169.46, 163.46, 163.11, 149.07, 138.51, 130.53, 125.93, 124.51, 122.23, 104.18, 96.13, 49.73, 46.56, 39.47, 33.90, 21.16, 20.96, 20.16, 18.79, 11.38; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{29}\text{H}_{46}\text{N}_2\text{O}_4\text{SiNa}$: 537.3125; found: 537.3133.




^1H NMR (400 MHz, CDCl_3) δ 7.17 (d, J = 1.6 Hz, 2H), 6.87 (br s, 1H), 4.65 – 4.54 (m, 1H), 3.63 (dd, J = 13.0, 7.0 Hz, 2H), 3.49 – 3.42 (m, 1H), 3.30 (dd, J = 9.3, 5.1 Hz, 2H), 2.27 (s, 3H), 1.39 (d, J = 6.8 Hz, 6H), 1.16 (d, J = 6.7 Hz, 6H), 1.11 (d, J = 3.0 Hz, 36H), 1.07 (dd, J = 10.9, 3.5 Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 169.22, 162.93, 162.80, 148.56, 140.54, 126.23, 125.25, 103.88, 96.57, 49.50, 46.54, 39.18, 32.28, 21.12, 20.96, 20.17, 18.82, 11.39; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{42}\text{H}_{68}\text{N}_2\text{O}_6\text{Si}_2\text{Na}$: 775.4514; found: 775.4530.




^1H NMR (400 MHz, CDCl_3) δ 7.48 (dd, J = 7.7, 0.9 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.25 (dd, J = 7.6, 1.4 Hz, 1H), 7.15 (td, J = 7.6, 1.6 Hz, 1H), 6.60 (br s, 1H), 4.41 – 4.35 (m, 1H), 3.72 – 3.59 (m, 2H), 3.57 – 3.50 (m, 1H), 3.47 – 3.40 (m, 1H), 1.37 (dd, J = 6.8, 1.7 Hz, 6H), 1.30 (d, J = 6.7 Hz, 3H), 1.13 (d, J = 2.7 Hz, 6H), 1.12 (d, J = 2.0 Hz, 18H), 1.08 (d, J = 9.8 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.49, 163.41, 145.49, 133.46, 128.97, 126.40, 125.84, 123.26, 105.25, 95.45, 49.75, 46.43, 44.30, 37.35, 20.92, 20.86, 20.18, 20.13, 18.80, 18.64, 11.45; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{28}\text{H}_{46}\text{N}_2\text{O}_2\text{SiNa}$: 493.3226; found: 493.3221.




^1H NMR (400 MHz, CDCl_3) δ 7.43 (d, J = 7.7 Hz, 2H), 7.09 (t, J = 7.7 Hz, 1H), 6.60 (br s, 1H), 4.57 – 4.50 (m, 1H), 4.21 – 4.13 (m, 1H), 4.08 – 3.99 (m, 1H), 3.85 – 3.78 (m, 1H), 3.46 – 3.40 (m, 1H), 1.50 (dd, J = 7.1, 2.7 Hz, 3H), 1.36 (d, J = 6.8 Hz, 6H), 1.15 (s, 6H), 1.12 (d, J = 2.9 Hz, 36H), 1.09 – 0.99 (m, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.28, 162.94, 146.54, 126.28, 49.65, 46.44, 42.92, 38.37, 20.96, 20.25, 20.16, 18.82, 17.03, 11.50; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{39}\text{H}_{66}\text{N}_2\text{O}_2\text{Si}_2\text{Na}$: 673.4561; found: 673.4562.




¹H NMR (400 MHz, CDCl₃) δ 7.49 (d, *J* = 7.5 Hz, 1H), 7.27 (d, *J* = 2.6 Hz, 1H), 7.26 (br s, 1H), 7.24 – 7.20 (m, 1H), 7.18 (dd, *J* = 7.7, 3.6 Hz, 1H), 1.41 – 1.37 (m, 6H), 1.14 (d, *J* = 2.7 Hz, 18H), 1.12 (s, 6H), 1.11 – 1.08 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 171.48, 162.88, 162.47, 138.26, 133.18, 129.58, 128.68, 126.98, 123.85, 105.01, 95.55, 52.96, 52.51, 49.58, 46.51, 36.74, 20.98, 20.81, 20.17, 20.06, 18.80, 18.79, 11.41; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₉H₄₆N₂O₄SiNa: 537.3125; found: 537.3130.




¹H NMR (400 MHz, CDCl₃) δ 7.44 (d, *J* = 7.7 Hz, 2H), 7.14 (d, *J* = 7.7 Hz, 1H), 7.10 (d, *J* = 6.2 Hz, 1H), 5.13 – 5.06 (m, 1H), 3.98 – 3.92 (m, 1H), 3.74 (d, *J* = 2.5 Hz, 3H), 3.67 – 3.62 (m, 1H), 3.51 – 3.44 (m, 1H), 3.42 – 3.35 (m, 1H), 1.35 (dd, *J* = 6.8, 2.5 Hz, 6H), 1.14 (t, *J* = 3.6 Hz, 36H), 1.11 (d, *J* = 5.3 Hz, 3H), 1.07 (d, *J* = 6.1 Hz, 6H), 1.03 (d, *J* = 14.6 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 171.39, 163.23, 162.85, 140.31, 133.16, 126.79, 124.60, 104.54, 96.38, 52.43, 52.08, 49.51, 46.30, 35.31, 21.07, 20.79, 20.21, 20.02, 18.84, 18.83, 11.41; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₄₀H₆₆N₂O₄Si₂Na: 717.4459; found: 717.4469.




¹H NMR (400 MHz, CDCl₃) δ 7.19 (d, *J* = 8.6 Hz, 1H), 7.16 (br s, 1H), 7.13 (d, *J* = 2.4 Hz, 1H), 4.82 – 4.72 (m, 1H), 4.26 – 4.19 (m, 1H), 3.64 (s, 3H), 3.43 – 3.29 (m, 2H), 3.18 – 3.08 (m, 1H), 2.20 (s, 3H), 1.32 (dd, *J* = 6.8, 2.9 Hz, 6H), 1.08 (d, *J* = 6.2 Hz, 6H), 1.06 (d, *J* = 3.1 Hz, 18H), 1.01 (d, *J* = 8.8 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 171.35, 169.24, 162.90, 162.42, 149.34, 135.97, 130.58, 125.84, 125.01, 122.19, 103.97, 96.65, 52.85, 52.54, 49.66, 46.52, 36.23, 21.14, 20.89, 20.76, 20.17, 20.04, 18.76, 11.35; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₃₁H₄₈N₂O₆SiNa: 595.3179; found: 595.3187.




¹H NMR (400 MHz, CDCl₃) δ 7.18 (d, *J* = 1.9 Hz, 2H), 7.11 (d, *J* = 8.3 Hz, 1H), 5.12 – 5.05 (m, 1H), 4.03 – 3.97 (m, 1H), 3.74 (d, *J* = 2.5 Hz, 3H), 3.63 – 3.57 (m, 1H), 3.47 – 3.37 (m, 2H), 2.27 (s, 3H), 1.38 – 1.33 (m, 6H), 1.18 – 1.15 (m, 3H), 1.15 – 1.12 (m, 36H), 1.11 (d, *J* = 4.3 Hz, 3H), 1.10 – 1.07 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 171.30, 169.05, 163.20, 162.77, 148.88, 138.11, 126.22, 125.75, 103.68, 97.44, 52.48, 51.97, 49.64, 46.32, 35.03, 21.13, 20.94, 20.71, 20.23, 20.00, 18.83, 18.82, 11.38; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₄₂H₆₈N₂O₆Si₂Na: 775.4514; found: 775.4530.




¹H NMR (400 MHz, CDCl₃) δ 6.92 (s, 1H), 6.82 (br s, 1H), 6.74 (s, 1H), 4.68 – 4.61 (m, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.59 – 3.54 (m, 2H), 3.51 – 3.44 (m, 1H), 3.00 (t, *J* = 6.8 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.19 (d, *J* = 6.7 Hz, 6H), 1.13 (s, 18H), 1.12 – 1.06 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.42, 163.04, 149.64, 147.39, 134.46, 115.26, 114.93, 112.61, 105.41, 93.03, 56.14, 56.11, 49.65, 46.59, 39.72, 34.12, 20.98, 20.15, 18.86, 11.49; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₉H₄₈N₂O₄SiNa: 539.3281; found: 539.3272.




¹H NMR (400 MHz, CDCl₃) δ 6.96 (s, 1H), 6.90 (br s, 1H), 4.68 – 4.61 (m, 1H), 3.89 (s, 3H), 3.85 (s, 3H), 3.60 (dd, *J* = 12.7, 7.0 Hz, 2H), 3.49 – 3.43 (m, 1H), 3.25 (dd, *J* = 9.4, 4.9 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.16 (d, *J* = 6.7 Hz, 6H), 1.14 (s, 18H), 1.12 (d, *J* = 2.4 Hz, 18H), 1.10 – 0.99 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 162.92, 162.79, 151.97, 151.12, 136.48, 119.24, 119.20, 116.67, 104.80, 100.40, 100.36, 94.27, 61.07, 56.22, 49.47, 46.56, 39.44, 32.08, 31.08, 21.02, 20.19, 18.87, 18.83, 11.47; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₄₀H₆₈N₂O₄Si₂Na: 719.4615; found: 719.4611.




¹H NMR (400 MHz, CDCl₃) δ 7.35 (d, *J* = 2.0 Hz, 1H), 7.31 (br s, 1H), 7.04 (s, 1H), 4.64 – 4.57 (m, 1H), 3.60 – 3.55 (m, 2H), 3.49 – 3.42 (m, 1H), 3.20 (dd, *J* = 8.9, 5.0 Hz, 2H), 1.37 (d, *J* = 6.8 Hz, 6H), 1.16 (d, *J* = 6.7 Hz, 6H), 1.10 (d, *J* = 3.7 Hz, 18H), 1.09 – 1.04 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.30, 162.99, 139.01, 139.00, 134.11, 130.37, 127.63, 123.68, 104.51, 99.08, 49.58, 46.60, 39.00, 31.44, 21.34, 20.99, 20.14, 19.67, 18.85, 11.46; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₇H₄₂Cl₂N₂O₂SiNa: 547.2290; found: 547.2280.



¹H NMR (400 MHz, CDCl₃) δ 7.03 – 6.98 (m, 2H), 6.92 (br s, 1H), 4.75 – 4.66 (m, 1H), 3.58 – 3.52 (m, 2H), 3.48 (dd, *J* = 13.6, 6.8 Hz, 1H), 3.18 – 3.12 (m, 2H), 2.42 (s, 3H), 2.34 (s, 3H), 1.41 (d, *J* = 6.8 Hz, 6H), 1.20 (d, *J* = 6.7 Hz, 6H), 1.14 (d, *J* = 1.8 Hz, 18H), 1.13 – 1.07 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.04, 162.70, 137.17, 135.47, 132.49, 131.26, 129.53, 126.55, 102.97, 97.76, 49.44, 46.49, 38.23, 31.30, 20.81, 20.00, 18.65, 11.22; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₉H₄₈N₂O₂SiNa: 507.3383; found: 507.3375.




¹H NMR (400 MHz, CDCl₃) δ 7.05 (d, *J* = 5.2 Hz, 1H), 7.01 (d, *J* = 5.2 Hz, 1H), 6.94 (br s, 1H), 4.70 – 4.63 (m, 1H), 3.63 – 3.58 (m, 2H), 3.53 – 3.46 (m, 1H), 3.17 (t, *J* = 6.8 Hz, 2H), 1.41 (d, *J* = 6.8 Hz, 6H), 1.21 (d, *J* = 6.7 Hz, 6H), 1.11 (s, 18H), 1.08 – 1.04 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.39, 162.94, 144.90, 130.29, 122.83, 121.16, 100.89, 93.79, 49.73, 46.67, 39.94, 28.97, 21.01, 20.19, 18.83, 11.41; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₅H₄₂N₂O₂SSiNa: 485.2634; found: 485.2643.




¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.4 Hz, 1H), 7.87 (d, *J* = 8.2 Hz, 2H), 7.62 (d, *J* = 7.8 Hz, 1H), 7.38 (d, *J* = 6.9 Hz, 1H), 7.35 (br s, 1H), 7.28 (d, *J* = 7.6 Hz, 1H), 7.19 (d, *J* = 8.1 Hz, 2H), 4.79 – 4.73 (m, 1H), 4.44 – 4.37 (m, 1H), 3.49 (s, 3H), 3.45 (dd, *J* = 13.3, 6.5 Hz, 1H), 3.26 (d, *J* = 7.5 Hz, 2H), 2.33 (s, 3H), 1.41 (s, 6H), 1.20 (d, *J* = 4.9 Hz, 18H), 1.15 (s, 3H), 1.11 (d, *J* = 5.0 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ =171.21, 162.77, 162.06, 144.91, 135.95, 129.85, 128.78, 127.14, 126.57, 125.86, 124.10, 119.96, 119.67, 114.81, 104.29, 95.32, 52.58, 52.09, 49.61, 46.65, 28.80, 21.71, 20.92,


20.18, 20.13, 18.81, 11.54; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₃₆H₅₁N₃O₄SSiNa: 672.3267; found: 672.3271.




¹H NMR (400 MHz, CDCl₃) δ 6.77 (br s, 1H), 4.67 – 4.60 (m, 1H), 3.48 (dd, *J* = 13.6, 6.8 Hz, 1H), 3.41 (dd, *J* = 13.2, 6.9 Hz, 2H), 2.54 (t, *J* = 7.0 Hz, 2H), 2.16 (s, 2H), 2.10 (s, 2H), 1.61 – 1.54 (m, 4H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.20 (d, *J* = 6.7 Hz, 6H), 1.05 (s, 18H), 1.04 – 0.93 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ = 163.44, 163.25, 142.79, 117.81, 107.45, 92.48, 49.74, 46.53, 37.77, 35.80, 30.18, 29.35, 22.50, 22.35, 21.00, 20.17, 18.81, 11.41; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₇H₄₈N₂O₂SiNa: 483.3383; found: 483.3379.




¹H NMR (400 MHz, CDCl₃) δ 6.88 (br s, 1H), 6.86 (s, 1H), 6.02 (s, 2H), 4.68 – 4.60 (m, 1H), 3.60 (d, *J* = 5.7 Hz, 2H), 3.50 – 3.43 (m, 1H), 3.25 (s, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.17 (d, *J* = 6.7 Hz, 6H), 1.12 (d, *J* = 3.0 Hz, 18H), 1.11 (d, *J* = 1.8 Hz, 18H), 1.08 (dd, *J* = 6.3, 4.6 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 162.94, 162.82, 150.37, 145.98, 137.35, 116.63, 112.25, 105.92, 105.03, 102.10, 100.30, 98.23, 93.53, 49.49, 46.56, 39.48, 32.06, 21.01, 20.19, 18.85, 18.82, 11.46, 11.39; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₃₉H₆₄N₂O₄Si₂Na: 703.4302; found: 703.4312.




¹H NMR (400 MHz, CDCl₃) δ 6.93 (br s, 1H), 6.00 (s, 1H), 4.78 – 4.71 (m, 1H), 3.55 (dd, *J* = 12.8, 6.5 Hz, 2H), 3.48 (dd, *J* = 13.6, 6.8 Hz, 1H), 2.68 (t, *J* = 6.7 Hz, 2H), 1.40 (d, *J* = 6.8 Hz, 6H), 1.20 (d, *J* = 6.7 Hz, 6H), 1.06 (d, *J* = 1.2 Hz, 36H), 1.05 – 0.99 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.06, 162.81, 133.13, 118.62, 106.61, 102.92, 102.79, 97.36, 49.57, 46.61, 37.75, 33.25, 20.97, 20.16, 18.73, 11.32, 11.30; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₃₄H₆₂N₂O₂Si₂Na: 609.4248; found: 609.4248.




¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, *J* = 8.5 Hz, 1H), 6.88 (br s, 1H), 6.75 (d, *J* = 2.3 Hz, 1H), 6.69 (dd, *J* = 8.5, 2.3 Hz, 1H), 4.63 – 4.56 (m, 1H), 3.78 (s, 3H), 3.62 – 3.54 (m, 2H), 3.50 – 3.43 (m, 1H), 3.02 (t, *J* = 6.8 Hz, 2H), 1.38 (d, *J* = 6.8 Hz, 6H), 1.18 (d, *J* = 6.7 Hz, 6H), 1.12 (d, *J* = 7.6 Hz, 18H), 1.09 – 1.04 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.42, 163.14, 159.81, 142.60, 134.43, 115.43, 114.79, 112.59, 105.31, 92.98, 55.37, 49.66, 46.49, 39.44, 34.56, 20.90, 20.11, 18.78, 11.43; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₈H₄₆N₂O₃SiNa: 509.3175; found: 509.3168.



¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, *J* = 8.6 Hz, 1H), 6.86 (br s, 1H), 6.69 (d, *J* = 8.7 Hz, 1H), 4.64 – 4.54 (m, 1H), 3.84 (s, 3H), 3.64 (dd, *J* = 12.7, 7.1 Hz, 2H), 3.49 – 3.42 (m, 1H), 3.32 (dd, *J* = 9.3, 5.1 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.15 (d, *J* = 6.7 Hz, 6H), 1.13 (d, *J* = 1.7 Hz, 18H), 1.12 (s, 18H), 1.10 – 0.94 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 162.98, 162.93, 161.36, 144.70, 134.03, 116.13, 113.61, 109.07, 104.96, 100.50, 100.45, 93.28, 56.08, 49.49, 46.51, 39.31, 32.71, 21.00, 20.20, 18.87, 18.84, 11.49; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₃₉H₆₆N₂O₃Si₂Na: 689.4510; found: 689.4503.




¹H NMR (400 MHz, CDCl₃) δ 7.38 (dd, *J* = 8.2, 3.2 Hz, 1H), 7.20 (d, *J* = 1.9 Hz, 1H), 7.14 (dd, *J* = 8.2, 2.0 Hz, 1H), 6.98 (br s, 1H), 4.64 – 4.57 (m, 1H), 3.62 – 3.57 (m, 2H), 3.51 – 3.44 (m, 1H), 3.02 (t, *J* = 6.9 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.20 (d, *J* = 6.7 Hz, 6H), 1.11 (d, *J* = 2.2 Hz, 18H), 1.10 – 1.04 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.42, 163.11, 142.69, 134.37, 134.20, 129.52, 126.83, 121.81, 104.05, 96.20, 49.75, 46.52, 39.27, 34.17, 20.92, 20.12, 18.75, 11.34; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₇H₄₃ClN₂O₂SiNa: 513.2680; found: 513.2669.




¹H NMR (400 MHz, CDCl₃) δ 7.37 (d, *J* = 1.4 Hz, 1H), 7.32 (d, *J* = 8.1 Hz, 1H), 7.30 (d, *J* = 1.7 Hz, 1H), 6.96 (br s, 1H), 4.66 – 4.59 (m, 1H), 3.61 – 3.56 (m, 2H), 3.52 – 3.45 (m, 1H), 3.02 (dd, *J* = 8.8, 5.2 Hz, 2H), 1.39 (d, *J* = 6.8 Hz, 6H), 1.20 (d, *J* = 6.7 Hz, 6H), 1.11 (d, *J* = 2.5 Hz, 18H), 1.07 (dd, *J* = 9.4, 5.1 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.40, 163.02, 142.86, 134.39, 132.42, 129.80, 122.69, 122.29, 104.11, 96.50, 49.74, 46.58, 39.33, 34.17, 20.98, 20.15, 18.77, 11.36; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₈H₄₃BrN₂O₂SiNa: 557.2175; found: 557.2158.


6. *ortho*-Alkynylation of γ -Arylpropamine Derivatives




A mixture of **4** (0.2 mmol, 1.0 equiv), **2** (0.4 mmol, 2 equiv), $\text{Pd}(\text{OAc})_2$ (1.1 mg, 0.05 equiv), AgOAc (66.8 mg, 2 equiv), KOAc (58.9 mg, 2 equiv), toluene (1 mL) in a 25 mL glass vial (purged with Ar, sealed with PTFE cap) was heated at 120 °C for 36 hours. The reaction mixture was cooled to rt, and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel to give the alkynylation product.




^1H NMR (400 MHz, CDCl_3) δ 7.83 (br s, 1H), 7.03 (dd, $J = 7.8, 1.7$ Hz, 1H), 6.98 (t, $J = 7.9$ Hz, 1H), 6.88 (dd, $J = 8.0, 1.6$ Hz, 1H), 4.64 – 4.57 (m, 1H), 4.27 – 4.22 (m, 2H), 3.89 (s, 3H), 3.60 – 3.55 (m, 2H), 3.51 (dd, $J = 13.6, 6.8$ Hz, 1H), 1.44 (d, $J = 6.8$ Hz, 6H), 1.22 (d, $J = 6.7$ Hz, 6H), 1.12 (d, $J = 1.6$ Hz, 18H), 1.08 (dd, $J = 8.0, 5.6$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.77, 163.42, 152.58, 149.19, 125.74, 124.39, 118.72, 112.74, 102.59, 95.90, 72.08, 56.05, 49.75, 46.43, 39.60, 20.98, 20.16, 18.76, 11.41; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for $\text{C}_{28}\text{H}_{46}\text{N}_2\text{O}_4\text{SiNa}$: 525.3125; found: 525.3124.




^1H NMR (400 MHz, CDCl_3) δ 7.29 (br s, 1H), 7.20 (d, $J = 7.7$ Hz, 1H), 7.05 (dd, $J = 13.8, 5.0$ Hz, 1H), 6.97 – 6.92 (m, 1H), 4.68 – 4.62 (m, 1H), 4.29 (t, $J = 5.0$ Hz, 2H), 3.65 (dd, $J = 10.7, 5.4$ Hz, 2H), 3.54 – 3.47 (m, 1H), 1.42 (d, $J = 6.8$ Hz, 6H), 1.22 (d, $J = 6.7$ Hz, 6H), 1.12 (d, $J = 2.3$ Hz, 18H), 1.07 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.65, 162.95, 155.41 (d, $J_{C-F} = 245$ Hz), 147.65 (d, $J_{C-F} = 12$ Hz), 129.50 (d, $J_{C-F} = 3$ Hz), 123.97 (d, $J_{C-F} = 8$ Hz), 119.36, 117.29 (d, $J_{C-F} = 19$ Hz), 101.68 (d, $J_{C-F} = 4$ Hz), 97.02, 72.48 (d, $J_{C-F} = 3$ Hz), 49.77, 46.59, 39.55, 20.94, 20.15, 18.76, 11.38; ^{19}F NMR (376 MHz, CDCl_3) δ -130.58; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for $\text{C}_{27}\text{H}_{43}\text{FN}_2\text{O}_3\text{SiNa}$: 513.2925; found: 513.2927.




¹H NMR (400 MHz, CDCl₃) δ = 7.40 (br s, 1H), 7.36 – 7.31 (m, 2H), 6.98 (t, *J* = 7.9 Hz, 1H), 4.72 – 4.65 (m, 1H), 4.31 (t, *J* = 5.1 Hz, 2H), 3.68 (dd, *J* = 10.5, 5.5 Hz, 2H), 3.54 – 3.47 (m, 1H), 1.43 (d, *J* = 6.8 Hz, 6H), 1.22 (d, *J* = 6.7 Hz, 6H), 1.12 (d, *J* = 2.7 Hz, 18H), 1.11 – 1.06 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ = 163.59, 162.91, 155.69, 133.02, 130.72, 128.07, 124.69, 119.35, 101.94, 97.38, 72.06, 49.73, 46.61, 39.63, 21.01, 20.16, 18.78, 11.40; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₇H₄₃ClN₂O₃SiNa: 529.2629; found: 529.2625.



¹H NMR (400 MHz, CDCl₃) δ = 7.35 (br s, 1H), 7.29 (dd, *J* = 7.6, 1.3 Hz, 1H), 7.12 (dd, *J* = 7.5, 0.8 Hz, 1H), 6.93 (t, *J* = 7.6 Hz, 1H), 4.79 – 4.72 (m, 1H), 4.24 (t, *J* = 5.2 Hz, 2H), 3.68 (dd, *J* = 10.9, 5.5 Hz, 2H), 3.55 – 3.48 (m, 1H), 2.26 (s, 3H), 1.43 (d, *J* = 6.8 Hz, 6H), 1.23 (d, *J* = 6.7 Hz, 6H), 1.12 (s, 18H), 1.11 – 1.05 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ = 163.45, 162.77, 158.04, 132.44, 131.71, 131.25, 123.74, 116.92, 103.68, 95.37, 71.00, 49.68, 46.68, 39.88, 21.00, 20.15, 18.81, 16.41, 11.46; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₈H₄₃N₂O₃SiNa: 509.3175; found: 509.3176.




¹H NMR (400 MHz, CDCl₃) δ 7.35 (d, *J* = 8.2 Hz, 1H), 7.21 (br s, 1H), 6.89 (dd, *J* = 8.2, 1.9 Hz, 1H), 6.81 (d, *J* = 1.8 Hz, 1H), 4.73 – 4.67 (m, 1H), 4.10 (t, *J* = 5.2 Hz, 2H), 3.72 (dd, *J* = 11.0, 5.5 Hz, 2H), 3.54 – 3.47 (m, 1H), 1.41 (d, *J* = 6.8 Hz, 6H), 1.22 (d, *J* = 6.7 Hz, 6H), 1.13 (s, 18H), 1.09 (dd, *J* = 9.3, 3.8 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.57, 162.44, 159.99, 135.20, 134.59, 121.25, 112.70, 111.96, 101.84, 96.36, 67.44, 49.71, 46.73, 38.86, 21.00, 20.14, 18.84, 11.41; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₂₇H₄₃ClN₂O₃SiNa: 529.2629; found: 529.2619.




¹H NMR (400 MHz, CDCl₃) δ 7.31 (d, *J* = 7.7 Hz, 1H), 7.18 (br s, 1H), 6.74 – 6.69 (m, 1H), 6.63 (s, 1H), 4.69 – 4.62 (m, 1H), 4.11 (t, *J* = 5.2 Hz, 2H), 3.72 (dd, *J* = 10.9, 5.5 Hz, 2H), 3.53 – 3.46 (m, 1H), 2.32 (s, 3H), 1.41 (d, *J* = 6.8 Hz, 6H), 1.21 (d, *J* = 6.7 Hz, 6H), 1.13 (s, 18H), 1.09 (dd, *J* = 7.1, 4.5 Hz,


3H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.67, 162.68, 159.44, 140.41, 133.80, 121.82, 113.05, 110.39, 103.23, 94.19, 67.15, 49.73, 46.64, 39.04, 21.97, 20.97, 20.13, 18.86, 11.46; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{28}\text{H}_{46}\text{N}_2\text{O}_3\text{SiNa}$: 509.3175; found: 509.3172.




^1H NMR (400 MHz, CDCl_3) δ 7.46 (d, $J = 7.6$ Hz, 1H), 7.25 – 7.21 (m, 1H), 7.18 (d, $J = 6.6$ Hz, 1H), 7.14 (dd, $J = 11.7, 4.4$ Hz, 1H), 6.97 (br s, 1H), 4.81 – 4.70 (m, 1H), 3.54 – 3.47 (m, 1H), 3.31 (d, $J = 6.8$ Hz, 2H), 2.91 – 2.81 (m, 2H), 1.92 (s, 2H), 1.42 (d, $J = 6.8$ Hz, 6H), 1.22 (d, $J = 6.8$ Hz, 6H), 1.13 (s, 18H), 1.08 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.24, 163.14, 143.55, 133.19, 128.96, 128.68, 126.12, 123.01, 105.51, 94.54, 49.74, 46.70, 39.19, 32.32, 30.02, 21.00, 20.19, 18.83, 11.45; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{28}\text{H}_{46}\text{N}_2\text{O}_2\text{SiNa}$: 493.3226; found: 493.3227.




^1H NMR (400 MHz, CDCl_3) δ 7.42 (d, $J = 7.7$ Hz, 1H), 7.09 (t, $J = 7.7$ Hz, 1H), 6.76 (br s, 1H), 4.79 – 4.72 (m, 1H), 3.53 – 3.46 (m, 1H), 3.35 (dd, $J = 15.3, 6.0$ Hz, 1H), 3.18 – 3.08 (m, 1H), 1.98 – 1.88 (m, 1H), 1.41 (d, $J = 6.8$ Hz, 3H), 1.21 (d, $J = 6.7$ Hz, 3H), 1.13 (d, $J = 2.4$ Hz, 18H), 1.09 (d, $J = 2.4$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 162.90, 145.75, 133.29, 125.97, 123.60, 105.08, 94.97, 49.59, 46.64, 39.60, 31.12, 29.70, 21.01, 20.21, 18.84, 11.44; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{39}\text{H}_{66}\text{N}_2\text{O}_2\text{Si}_2\text{Na}$: 673.4561; found: 673.4563.



^1H NMR (400 MHz, CDCl_3) δ 7.47 (d, $J = 7.6$ Hz, 1H), 7.33 (d, $J = 7.4$ Hz, 2H), 7.27 (d, $J = 7.2$ Hz, 2H), 7.25 (s, 1H), 7.23 (d, $J = 6.5$ Hz, 1H), 7.16 (dd, $J = 11.0, 3.6$ Hz, 1H), 7.14 – 7.10 (m, 1H), 6.97 (br s, 1H), 4.80 – 4.68 (m, 2H), 3.52 – 3.45 (m, 1H), 3.33 – 3.17 (m, 2H), 2.41 – 2.29 (m, 2H), 1.40 (d, $J = 6.8$ Hz, 6H), 1.21 (d, $J = 6.6$ Hz, 6H), 1.16 (s, 18H), 1.11 (d, $J = 10.2$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 163.09, 162.89, 146.05, 143.47, 133.54, 129.03, 128.60, 127.92, 126.77, 126.50, 126.22, 123.17, 105.87, 95.38, 49.57, 46.66, 46.14, 38.60, 34.94, 20.98, 20.14, 18.87, 11.49; HRMS (ESI-TOF) m/z [M+Na] $^+$ Calcd for $\text{C}_{34}\text{H}_{50}\text{N}_2\text{O}_2\text{SiNa}$: 569.3539; found: 569.3532.




¹H NMR (400 MHz, CDCl₃) δ = 7.22 (d, *J* = 8.2 Hz, 1H), 7.10 (d, *J* = 8.5 Hz, 1H), 6.98 (d, *J* = 2.7 Hz, 1H), 6.80 (dd, *J* = 8.5, 2.8 Hz, 1H), 4.72 – 4.66 (m, 1H), 4.54 – 4.48 (m, 1H), 3.77 (s, 3H), 3.68 (s, 3H), 3.55 – 3.48 (m, 1H), 2.88 – 2.79 (m, 2H), 2.35 – 2.27 (m, 1H), 2.06 – 1.97 (m, 1H), 1.44 (d, *J* = 6.8 Hz, 6H), 1.23 (d, *J* = 6.6 Hz, 6H), 1.13 (d, *J* = 1.5 Hz, 18H), 1.08 (dd, *J* = 9.4, 5.0 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ = 172.12, 163.17, 162.45, 157.82, 134.88, 130.26, 123.80, 117.99, 115.11, 105.30, 94.67, 55.50, 52.47, 52.00, 49.73, 46.73, 32.81, 30.18, 21.00, 20.98, 20.22, 20.16, 18.83, 11.43; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₃₁H₅₀N₂O₅SiNa: 581.3387; found: 581.3381.



¹H NMR (400 MHz, CDCl₃) δ 7.05 (d, *J* = 8.1 Hz, 1H), 6.96 (d, *J* = 1.8 Hz, 2H), 4.75 – 4.68 (m, 1H), 4.63 – 4.56 (m, 1H), 3.78 (s, 3H), 3.69 (s, 3H), 3.54 – 3.47 (m, 1H), 3.17 – 3.02 (m, 2H), 2.18 – 2.10 (m, 1H), 2.06 – 1.99 (m, 1H), 1.42 (dd, *J* = 6.8, 4.3 Hz, 6H), 1.22 (dd, *J* = 8.1, 6.8 Hz, 6H), 1.16 – 1.13 (m, 36H), 1.13 – 1.07 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 171.95, 163.23, 162.18, 157.21, 137.32, 124.40, 119.14, 104.88, 95.02, 55.65, 53.11, 52.35, 49.57, 46.69, 32.34, 29.73, 21.05, 21.02, 20.22, 20.18, 18.89, 11.42; HRMS (ESI-TOF) m/z [M+Na]⁺ Calcd for C₄₂H₇₀N₂O₅Si₂Na: 761.4721; found: 761.4721.

7. Gram Scale Reaction


Scheme 1S Gram Scale Reaction.




A mixture of **1a** (1.226 g, 4 mmol, 1.0 equiv), **2** (1.568 g, 6 mmol, 1.5 equiv), Pd(OAc)₂ (11 mg, 0.025 equiv), CsOAc (1.536 g, 2 equiv) and toluene (10 mL) in a 50 mL glass vial (sealed with PTFE cap) was heated at 100 °C for 48 hours. The reaction mixture was cooled to rt, and concentrated in vacuo. The resulting residue was purified by column chromatography on silica gel to give **3a** as yellow solid in 82% yield.

8. Removal of the TIPS^[6]

Scheme 2S Removal of the TIPS.




3a (0.146 g, 0.3 mmol) was dissolved in dry THF (10 mL). After cooling to 0 °C TBAF (400 μL, 0.4 mmol, 1M solution in THF) were added and the reaction mixture stirred for 1h. Then some drops of water and CH₂Cl₂ (20 mL) were added. The organic layer was washed three times with water and dried over MgSO₄. After evaporation of the solvent the residue was purified by column chromatography on silica gel afforded **6a** as pale yellow solid in 98% yield.




¹H NMR (400 MHz, CDCl₃) δ 7.16 (br s, 1H), 7.10 – 7.05 (m, 1H), 7.04 – 7.00 (m, 1H), 4.52 – 4.46 (m, 1H), 3.77 (s, 3H), 3.48 (dd, *J* = 12.5, 6.7 Hz, 2H), 3.44 – 3.37 (m, 1H), 3.22 (s, 1H), 3.07 (t, *J* = 6.8 Hz, 2H), 1.34 (d, *J* = 6.8 Hz, 6H), 1.10 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.34, 163.31, 157.43, 129.90, 127.35, 124.93, 123.24, 111.10, 81.88, 81.02, 55.45, 49.41, 46.20, 39.06, 27.39, 20.74, 19.94; HRMS (ESI-TOF) m/z [M+H]⁺ Calcd for C₁₉H₂₇N₂O₃: 331.2022; found: 331.2017.

9. Removal of the Directing Group^[7]

Scheme 3S Removal of the Directing Group.




A mixture of **3a** (0.146 g, 0.3 mmol, 1.0 equiv) in THF (2 mL) was stirred for 10 min at -10 °C, NaH (60 %) (0.06 g, 2.5 mmol, 5.0 equiv) was slowly added, and then stirred for another 1 hour. NsCl (0.1 g, 7.5 mmol, 1.5 equiv) was added slowly for thirty minutes. The mixture was stirred over night at room temperature and heated at 60 °C for another 12 hours. The reaction mixture was cooled to rt, quenched with water (20 mL), extracted with CH₂Cl₂ (10 mL × 2). The combined organic phase was washed with brine (20 mL), dried over anhydrous Na₂SO₄. Evaporation and column chromatography on silica gel afforded **7a** as pale yellow solid in 73% yield.




¹H NMR (400 MHz, CDCl₃) δ 8.11 (d, *J* = 8.9 Hz, 2H), 7.71 (d, *J* = 8.9 Hz, 2H), 7.09 (t, *J* = 8.0 Hz, 1H), 6.95 (dd, *J* = 7.7, 0.9 Hz, 1H), 5.02 (br s, 1H), 3.79 (s, 3H), 3.41 – 3.30 (m, 2H), 3.07 – 2.98 (m, 2H), 1.14 (d, *J* = 2.6 Hz, 18H), 1.06 (d, *J* = 6.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 157.22, 145.43, 128.32, 127.93, 127.87, 125.60, 124.83, 124.03, 111.02, 104.84, 95.92, 55.90, 43.30, 27.32, 18.83, 11.42; HRMS (ESI-TOF) m/z [M+H]⁺ Calcd for C₂₆H₃₇N₂O₅SSI: 517.2192; found: 517.2187.

10. Synthesis of 3,4-Dihydroisoquinoline 8a

Scheme 4S Synthesis of 3,4-Dihydroisoquinoline 8a.



A mixture of **3a** (0.146 g, 0.3 mmol, 1.0 equiv) and NaOH (0.06 g, 1.5 mmol, 5.0 equiv) in EtOH (2 mL) was stirred at 80 °C for 12 hours. The reaction mixture was cooled to rt, then some drops of water and CH₂Cl₂ (20 mL) were added. The organic layer was washed three times with water and dried over MgSO₄. After evaporation of the solvent the residue was purified by column chromatography on silica gel afforded **8a** as pale yellow solid in 65% yield.



¹H NMR (400 MHz, CDCl₃) δ 7.33 (t, *J* = 8.0 Hz, 1H), 7.23 (d, *J* = 7.6 Hz, 1H), 7.07 (d, *J* = 8.2 Hz, 1H), 3.87 (s, 3H), 3.76 – 3.71 (m, 2H), 2.85 – 2.80 (m, 2H), 2.61 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 156.08, 128.91, 127.89, 125.89, 119.18, 114.92, 55.89, 44.29, 29.84, 22.22, 18.71; HRMS (ESI-TOF) m/z [M+H]⁺ Calcd for C₁₁H₁₄NO: 176.1075; found: 176.1070.

11. Optimization of Protecting Group

Table 2S Optimization of Protecting Group

	+ Br-C≡N-TIPS 1.5 eq	Pd(OAc) ₂ (5 mol%) KOA _c (2 equiv) AgOAc (2 equiv) toluene (1 mL) 120 °C, Ar, 36h	
PG =			Ac
		21%	0%
		0%	0%
		0%	0%
		0%	0%
		:	
		= 10 : 1	


A variety of protecting group for γ -Arylpropamine had been tested: However none could give synthetic acceptable yield. It worth to note that the picolinamide assisted alkynylation gave a mixture of γ and ε -alkynylated products analyzed by proton NMR.

12. Alkynylation of different substituted bromoalkyne

Table 3S Alkynylation of different substituted bromoalkyne

	+ Br-C≡R 2x, 2 equiv	Pd(OAc) ₂ (5 mol%) CsOAc (2 equiv) toluene (1 mL) 100 °C, air, 24h	
1a, 0.2 mmol			
			9a, 46% 9b, 0%


We had tested the alkyl and aryl alkynyl bromide under standard condition. The alkyl alkynyl bromide (**2a**) gave the desired products in 46% isolated yield. Unfortunately, the aryl alkynyl bromide (**2b**) failed to give any alkynylated product, only starting material recovered.



¹H NMR (400 MHz, CDCl₃) δ 7.11 (d, *J* = 7.9 Hz, 1H), 7.08 (br s, 1H), 6.99 (dd, *J* = 7.7, 0.8 Hz, 1H), 6.78 (d, *J* = 7.9 Hz, 1H), 4.58 – 4.51 (m, 1H), 3.82 (s, 3H), 3.55 – 3.50 (m, 2H), 3.45 (dd, *J* = 13.6, 6.8 Hz, 1H), 1.40 (d, *J* = 6.8 Hz, 6H), 1.32 (s, 9H), 1.14 (d, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.47, 163.41, 157.52, 129.20, 127.31, 125.27, 124.52, 110.05, 102.79, 55.60, 49.55, 46.43, 39.62, 31.11, 28.28, 27.24, 20.95, 20.17; HRMS (ESI-TOF) m/z [M+H]⁺ Calcd for C₂₃H₃₅N₂O₃: 387.2648; found: 387.2645.

13. Alkynylation of δ -Arylbutamine Derivatives

Scheme 5S Alkynylation of δ -Arylbutamine Derivatives.



We had tested the delta-amide (**4j**) under standard condition. However it failed to give any delta-position alkynylated product. In fact a mixture of γ and δ -alkynylated product was observed which was analyzed by proton NMR.

14. References

- [1] T.-S. Mei, X. Wang and J.-Q. Yu, *J. Am. Chem. Soc.*, 2009, **131**, 10806.
- [2] G. Xu and S. R. Gilbertson, *Org. Lett.*, 2005, **7**, 4605.
- [3] G. He, C. Lu, Y. Zhao, W. A. Nack and G. Chen, *Org. Lett.*, 2012, **14**, 2944.
- [4] J. Han, P. Liu, C. Wang, Q. Wang, J.-Y. Zhang, Y.-W. Zhao, D.-Q. Shi, Z.-B. Huang and Y.-S. Zhao, *Org. Lett.*, 2014, **16**, 5682.
- [5] C. Wang, C.-P. Chen, J.-Y. Zhang, Y.-M. Yao and Y.-S. Zhao, *Angew. Chem.*, 2014, **126**, 10042; *Angew. Chem., Int. Ed.*, 2014, **53**, 9884.
- [6] F. Wessendorf, B. Grimm, D. M. Guldi and A. Hirsch, *J. Am. Chem. Soc.*, 2010, **132**, 10786.
- [7] C.-P. Chen, C. Wang, J.-Y. Zhang and Y.-S. Zhao, *J. Org. Chem.*, 2015, **80**, 942.

15. NMR spectra

